What role should government have in drug pricing?
Headlines about pricey drugs and medical devices this past year ignited political discussions about drug price control measures. Experts from USC and the United Kingdom will explain and debate the pros and cons of price controls at a panel discussion on Monday, April 3.
Contact: Emily Gersema, (213) 361-6730 or gersema@usc.edu
WHAT: “What Role Should Government Play in Drug Price Negotiations?”
The experts will discuss issues such as:
- The politics of imposing drug price controls and increased interest among voters
- Proposals under consideration by Congress and the Trump administration, such as allowing for
- Medicare to negotiate drug prices directly with manufacturers
- Potential impact, negative and positive, of negotiating drug prices
- Factors that influence drug pricing, drug research and development
- Other nations’ efforts to regulate drug prices
**RSVP here with the code drugprice, or contact Emily Gersema at (213) 361-6730 or gersema@usc.edu**
WHEN: Monday, April 3, 10:30 a.m.-11:45 a.m.
WHERE: Ronald Tutor Campus Center at USC, 3607 Trousdale Pkwy, Los Angeles, CA 90089 in The Forum (Room 450)
WHO: The discussion will be moderated by Dana Goldman, professor and Leonard D. Schaeffer Chair and director of the USC Schaeffer Center for Health Policy and Economics.
The panelists are:
Sir Michael Rawlins, chair of the United Kingdom’s Medicines and Healthcare Products Regulatory Agency, which oversees drugs and medical device regulations. He is the former chair of the National Institute for Health and Care Excellence in the UK.
Neeraj Sood, professor and vice dean for research at the USC Price School of Public Policy and director of research at the USC Schaeffer Center for Health Policy and Economics
David Lazarus, award-winning business columnist for The Los Angeles Times, focusing on consumer affairs
# # #